Dr. Adaora Adimora On How HIV Impacts Women and Minorities

For National Women and Girls HIV/AIDS Awareness Day, AIDSVu spoke with Dr. Adaora Adimora about increasing the rate of PrEP use among women and minorities impacted by HIV.

Adaora Adimora, MD, MPH, is a Professor of Epidemiology at the UNC School of Medicine and Co-Director of the Center for AIDS Research.

Q: Your career has largely focused on the epidemiology of STDs and HIV in women and minorities. What drove you towards this specific line of research?

A: For a long time, we have observed marked differences in the rate of STIs between Blacks and whites. Soon after HIV came on the scene, differences between Blacks and whites were observed with HIV as well. Back in the 1980s and early 1990s, there was an emphasis on “risk behavior” and “risk groups”. An underlying implication was that Black people in general had “higher risk” sexual behavior than whites. As a Black person with involvement in the Black community, that generalization just did not ring true to me. One thing I noticed was that a portion of Black people I saw with HIV, especially women, had behaviors that did not differ significantly from those of the general population. Some of them had few sexual partners, no drug use. Many didn’t have partners who use drugs or partners who were men who have sex with men (MSM).

Around the same time in the early-to-mid 1990s, there was increasing interest in sexual network patterns and the spread of infection through networks of connected people. Martina Morris, for example, was publishing her groundbreaking work about concurrent partnerships, which is when an individual has overlapping sexual relationships with more than one person. It seemed to me that this could be contributing to the higher rates of HIV and other STIs among Black people. To be clear, this is not saying that Black people have different moral standards, or that whites don’t engage in these behaviors. Rather, it was clear from my own lived experience as a Black person—and from the work of sociologists like William Julius Wilson—that larger social forces like macroeconomics, racism, and their associated effects likely influence behaviors that increase the vulnerability of Black Americans to HIV and worsen health outcomes.

Importantly, the work of the late Paul Farmer introduced me to the idea of structural violence, which is a concept that was first written about by Johan Galtung in the 1960s. This concept stresses that these forces are structural, that they are baked into the system, and that they damage people in a way that limits their life chances. These forces are also so ordinary that they’re almost invisible. The idea is that, although people’s individual behaviors affect their likelihood of getting HIV and other STIs, there are larger systemic forces that affect groups of people unequally and increase their vulnerability to these infections, as well as worsen their outcomes once they have them.

Q: As part of a six-paper series in The Lancet, you authored a paper titled “HIV and women in the USA: what we know and where to go from here”. In it, you address the U.S. plan to end the HIV epidemic by 2030. What are the unique factors impacting women in the HIV epidemic and how will addressing those specifically help us reach our goals?

A: Black and Hispanic/Latina women are disproportionately affected by HIV compared to white women. The factors that impact women in the HIV epidemic are mostly those, in my view, that are associated with being an oppressed racial minority in the United States. In addition, there are strong intersectional and probably synergistic links between race, poverty, sexism, and HIV. While men who have sex with men bear the lion’s share of the burden of HIV in this country, almost one in five new HIV infections in the U.S. are among women. We will never end the HIV epidemic without attending to HIV among women, as well as the socio-economic factors that contribute to it.

Q: Part of your paper focuses on PrEP use among women. You mention that although the annual percentage change in PrEP use among U.S. men increased by 68% from 2012 to 2017, use among women during the same period only increased by only 5.4%. What factors did you identify that account for this drastic difference?

A: There are several major reasons. First, many women haven’t heard about PrEP at all. In addition, many of those who have heard of it do not think its use is applicable to them, so they don’t ask for it. Second, I suspect that some providers are not comfortable prescribing PrEP at all. Third, some providers do not think of offering PrEP to their female patients or exploring whether its use is warranted. I think some providers make assumptions about their patient’s behavior and the behavior of their patient’s partners or aren’t comfortable talking about sex in general. Consequently, they may not realize that the female patient in front of them might benefit from PrEP.

Fourth, cost is an issue and for uninsured people, and the paperwork required to get free PrEP may be a barrier. Fifth, and this is a huge reason, there is often too little time in the office visit or clinical encounter. Providers are supposed to talk about smoking, screening exams, exercise, mental health, and intimate partner violence, as well as the patient’s existing medical problems, and anything else the patient wants to talk about. You can therefore imagine that providers may have difficulty prioritizing sexual health—including PrEP—during an office visit that is 30 minutes or less, especially if it is not obvious to them that the patient needs or wants PrEP.

Q: Your paper also notes that women are under-represented both in HIV research and as subjects in clinical trials. What effect does this underrepresentation have on health outcomes for women? What recommendations do you suggest for increasing the inclusion of women in this field?

A: It is important to note that women are not just men with estrogen. In addition to hormonal and physiological influences that differ by sex, the context of life differs substantially between men and women. The paucity of women in research means that there is less data to understand the health outcomes and conditions that affect them, how these conditions manifest, and how to treat them. We also need to understand how women feel about biomedical products and whether they can access and use them. Products cannot work if they’re not used. A lack of data on women puts them at risk for being left behind by biomedical advances.

In terms of what can be done to increase the inclusion of women in this field or in research generally, researchers need to remember that participation in a clinical trial is a tremendous act of altruism. Research staff should approach them with respect and consideration, and women need to be properly compensated for their time and the unique difficulties that they may have with transportation, childcare, and jobs. Many women may not have the autonomy that men with higher incomes or higher status jobs might have to easily take time off from work to participate in a trial. Working with community-based organizations and others from the community is also essential in terms of getting women into trials.  Funding agencies need to consider all of this as well. They can use carrots and sticks to strongly incentivize researchers to ensure that they include women in research that they’re funding.

Inclusion in clinical trials is critical, but the funders need to make sure that they properly consider other types of research, including qualitative and social science research that explores questions that are meaningful for women. Including, for example, how and why interventions do or don’t work, and their effects on quality of life.

Q: March 10 is National Women and Girls HIV/AIDS Awareness Day (NWGHAAD), which highlights the impact of HIV and AIDS on women and girls. What message do you have for women, girls, and their support community on this day?

A: While new infections among women in the US have decreased in recent years, now is not the time to be complacent. We need to continue our efforts, and in particular continue our fight for social and reproductive justice. One issue that we can all get behind is the need for healthcare coverage and access for all men and women. It is a disgrace that most of the states that have not expanded Medicaid are in some of the poorest areas with the highest rates of HIV, STIs, and other comorbid conditions. We need to vote in our own best interests and encourage others to do so as well.

This article was originally published on March 10th, 2022 on AIDSVu, and the original can be accessed here.

Margolis Elected Fellow to the American Association for the Advancement of Science

Margolis Headshot

David Margolis
(Jon Gardiner/UNC-Chapel Hill)

“David Margolis, MD, Sarah Graham Keenan Distinguished Professor of Medicine, Microbiology & Immunology, Epidemiology, has been elected fellow of the American Association for the Advancement of Science (AAAS). The prestigious honor recognizes distinguished contributions to the field of virology, particularly for making key discoveries on the mechanisms of HIV latency and devising new strategies to find a cure for HIV infection. He will be honored at an upcoming AAAS Annual Meeting.”

This story was originally published by the UNC Health and UNC School of Medicine Newsroom on August 17, 2021 – read more here.

 

Developmental Core Announces 2 new funding sources

In addition to its recent Microgrant, the UNC CFAR Developmental Core has released its 2022-2023 RFP and a CFAR Notice of Special Interest (NOSI): Request for Proposals of HIV/COVID-19 Small Grants. Letters of intent for these proposals are due no later than Wednesday, December 1, 2021. 

All current Developmental Core funding opportunities are linked below.

Microgrant (Rolling Deadline)

Traditional RFP

  • Contact the CFAR Developmental Core during application preparation for a telephone or email conversation to verify eligibility and briefly describe research idea
  • Letter of Intent Due Date: Wednesday, December 1, 2021
  • Application Due Date: Friday, January 7, 2022
  • CFAR Scientific Review: February 2022
  • Notification of Award: early March 2022
    • Actual start date may be delayed if required approvals are delayed; see below.
  • Period of Award: Funding expires on July 31, 2023, however, we ask that you spend as much of your funds as possible by July 31, 2022.

HIV/COVID-19 NOSI

  • Contact the CFAR Developmental Core during application preparation for a telephone or email conversation to verify eligibility and briefly describe research idea
  • Letter of Intent Due Date: Wednesday, December 1, 2021
  • Application Due Date: Friday, January 7, 2022
  • CFAR Scientific Review: February 2022
  • Notification of Award: early March 2022
    • Actual start date may be delayed if required approvals are delayed; see below.
  • Period of Award: Funding expires on July 31, 2023, however, we ask that you spend as much of your funds as possible by July 31, 2022.

 

Alicia Diggs named one of Plus+ Magazine’s 25 Amazing People of the Year (who are also living with HIV)

Alicia Diggs has been living with HIV for 20 of her 49 years, and she’s made good use of every year. Not only is she an author, a PhD, and a fierce advocate for people living with HIV, she’s also a member of the Presidential Advisory Council on HIV/AIDS, the manager for the Office of Community Engagement for the North Carolina-Chapel Hill Center for AIDS Research, and a member of many other HIV support organizations.

“Through my trials and tribulations, I made a decision to fight and stand strong as a woman living with HIV so that I can help my fellow brothers and sisters fight and stand strong,” she says about her decision to be a leader in her community. “It has been important to me to help build coalitions and solidarity within and amongst our diverse communities to that we can dispel the myths, rid the stigma, and educate others about HIV.”

Being included on this list reminds her that there are “so many amazing, inspiring, and fabulous leaders out there doing this work,” and that the work she does really does make a difference.

Before she became a leader herself, Diggs says she had other leaders and community members who supported, protected, and pushed her, and she wants to live up to that legacy, passing the torch to others like herself. 

“As people living with HIV, it is important to know that decisions about us cannot be made without us. Our voices and input are the key to ending the HIV epidemic,” she says. “If you feel like the door is not open to you, create your own door. If you feel there is not room for you at the table, create your own table. Do not take no for an answer and make sure that your voice is heard because you are the change we want and need to see in the world.”

 

The above article originally appeared in Plus+ magazine as part of their November/December 2021 issue. Read more here.

UNC HIV Cure Center Awarded $26.2 million over the next 5 Years

Margolis headshot“The National Institutes of Health will award $53 million annually to 10 research organizations over the next five years to continue working toward curative therapies for HIV. The Collaboratory of AIDS Researchers for Eradication (CARE), led at the UNC HIV Cure Center by David Margolis, MD, is one of two programs to have received funds for all three five-year grant cycles since 2011.”

This story was originally published by the UNC Health and UNC School of Medicine Newsroom on August 17, 2021 – read more here.

Study Compares Mortality Among People Entering HIV Care with General US Population

“HIV-related mortality has decreased since 1996 due to improving treatments and evolving care guidelines, but the extent to which persons entering HIV care have a higher risk for death over the following years, compared with peers in the general population, has been unclear.

Joseph Eron, MD, the Herman and Louise Smith Distinguished Professor of Medicine and chief of the division of infectious diseases, was the senior investigator on this novel observational study that advances the understanding of trends in mortality in the years after entering HIV care, compared with the general US population, published recently in the Annals of Internal Medicine.

The study was led by Jessie K. Edwards, PhD, assistant professor in the department of epidemiology, and utilized 13 sites from the North American AIDS Cohort Collaboration on Research and Design. Participants included 82,766 adults entering HIV clinical care between 1999 and 2017, and a subset of the US population, matched on calendar time, age, sex, race/ethnicity, and county using mortality and population data compiled by the National Center for Health Statistics.

The results showed a dramatic mortality decrease between 1999 and 2017, although those entering care remained at higher risk for death in the years after starting care than comparable adults in the general US population. Five-year mortality for people entering HIV care was 10.6%, and mortality among the matched U.S. population was 2.9%, for a difference of 7.7 (95% CI, 7.4 to 7.9) percentage points. This difference decreased over time, from 11.1 percentage points among those entering care between 1999 and 2004 to 2.7 percentage points among those entering care between 2011 and 2017.

“While we have seen substantial improvement in survival for people with HIV after they enter care, there is still a modest but real difference in survival compared to a carefully matched population of people without HIV,” Eron said. “Some of our patients still enter care years after infection and cannot take full advantage the improvements in treatment and care.”

Researchers acknowledge that understanding the differences in mortality between persons entering HIV care and the matched US population is critical to improving care, and that gaps still remain. Being able to quantify the elevation in mortality observed for persons in HIV care will inform future efforts to address both AIDS and non–AIDS-related consequences of HIV infection and long-term ART.

The study was supported by the National Institutes of Health; the Centers for Disease Control and Prevention; the Agency for Healthcare Research and Quality; the Health Resources and Services Administration; Grady Health System; the Canadian Institutes of Health Research; the Ontario Ministry of Health and Long-Term Care; and the Government of Alberta, Canada.”

This story was originally published by the UNC Department of Medicine on July 13, 2021 – read more here. 

Joseph Eron named to endowed chair

JE wearing white coat and maskUNC School of Medicine Dean Wesley Burks named Infectious Diseases Chief Joseph Eron, Jr., MD, the Herman and Louise Smith Distinguished Professor of Medicine on March 10, 2021. The honor acknowledges his decades-long commitment to infectious diseases along with his work this past year during the COVID-19 pandemic. We are honored to work with Dr. Eron, our CFAR Clinical Core Director!

Michael Hudgens Appointed Associate Chair of Biostatistics

Hudgens headshotMichael Hudgens, UNC CFAR Biostatistics Core Director, is the new Associate Chair of the Biostatistics Department! Dr. Hudgens joins Lisa LaVange, Department Chair, and brings many years of experience to UNC’s top-ranked biostatistics department. Hudgens has co-authored more than 200 peer-reviewed papers in statistical journals such as Biometrics, Biometrika, JASA and JRSS-B as well as biomedical journals such as the Lancet, Nature and New England Journal of Medicine. He currently serves as an Associate Editor for Biometrics, JASA and JRSS-B. He is an elected Fellow of the American Statistical Association and has taught graduate level biostatistics courses at UNC for over ten years. Congratulations!

Nature Highlights UNC HIV Research in ‘Best of’ List from 2020

Drs. Margolis, Garcia, and Dunham (left-to-right) pose in the Genetic Medicine Building

UNC-Chapel Hill HIV researchers David Margolis, MD, and J. Victor Garcia, PhD, along with Rick Dunham from ViiV Healthcare (from left to right). Margolis is director of the UNC HIV Cure Center, which is home to Qura Therapeutics, a company formed through a partnership between UNC-Chapel Hill and ViiV, formerly the HIV research wing of GSK.
Photographed January 21, 2020 at the Genetic Medicine Building on the campus of the University of North Carolina at Chapel Hill.
(Jon Gardiner/UNC-Chapel Hill)

UNC HIV researchers were featured in a recent Nature article titled, “Viruses, microscopy and fast radio bursts: 10 remarkable discoveries from 2020.” A study on HIV latency reversal from J. Victor Garcia, PhD, David Margolis, MD, and team (with Qura Therapeutics and Emory University) is listed as one of the 10 most remarkable discoveries of 2020!

Read more at the UNC Health and UNC School of Medicine Newsroom here.